Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Navigation/Suche

• Forscher*innen.
• Institutionen.
• Projekte.
• Publikationen.
• Partner.
• Geldgeber.
• Ausstattung.
• Knowhow.
• Forschungsfelder.

Publikationen

Suchbegriffe: INTERFERONS, . Treffer: 20

2022

Benkert, P; Meier, S; Schaedelin, S; Manouchehrinia, A; Yaldizli, Ö; Maceski, A; Oechtering, J; Achtnichts, L; Conen, D; Derfuss, T; Lalive, PH; Mueller, C; Müller, S; Naegelin, Y; Oksenberg, JR; Pot, C; Salmen, A; Willemse, E; Kockum, I; Blennow, K; Zetterberg, H; Gobbi, C; Kappos, L; Wiendl, H; Berger, K; Sormani, MP; Granziera, C; Piehl, F; Leppert, D; Kuhle, J, , NfL, Reference, Database, in, the, Swiss, Multiple, Sclerosis, Cohort, Study, Group Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
Lancet Neurol. 2022; 21(3): 246-257. Doi: 10.1016/S1474-4422(22)00009-6
Web of Science PubMed FullText FullText_MUG

 

Prinz, F; Jonas, K; Balihodzic, A; Klec, C; Reicher, A; Barth, DA; Riedl, J; Gerger, A; Kiesslich, T; Mayr, C; Rinner, B; Kargl, J; Pichler, M MicroRNA mimics can distort physiological microRNA effects on immune checkpoints by triggering an antiviral interferon response.
RNA Biol. 2022; 19(1):1305-1315 Doi: 10.1080/15476286.2022.2152978 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2021

Rech, L; Rainer, PP The Innate Immune cGAS-STING-Pathway in Cardiovascular Diseases - A Mini Review.
Front Cardiovasc Med. 2021; 8: 715903 Doi: 10.3389/fcvm.2021.715903 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2017

Ritter, C; Fan, K; Paschen, A; Reker Hardrup, S; Ferrone, S; Nghiem, P; Ugurel, S; Schrama, D; Becker, JC Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma.
Sci Rep. 2017; 7(1):2290-2290 Doi: 10.1038/s41598-017-02608-0 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2012

Klymiuk, I; Kenner, L; Adler, T; Busch, DH; Boersma, A; Irmler, M; Fridrich, B; Gailus-Durner, V; Fuchs, H; Leitner, N; Müller, M; Kühn, R; Schlederer, M; Treise, I; de Angelis, MH; Beckers, J In vivo functional requirement of the mouse Ifitm1 gene for germ cell development, interferon mediated immune response and somitogenesis.
PLoS One. 2012; 7(10): e44609-e44609. Doi: 10.1371/journal.pone.0044609 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2007

Haybaeck, J; Obrist, P; Schindler, CU; Spizzo, G; Doppler, W STAT-1 expression in human glioblastoma and peritumoral tissue.
Anticancer Res. 2007; 27(6B): 3829-3835. [OPEN ACCESS]
Web of Science PubMed FullText

 

Wolf, IH; Kodama, K; Cerroni, L; Kerl, H Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment.
Am J Dermatopathol. 2007; 29(3):237-241 Doi: 10.1097/01.dad.0000211531.33670.94
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2006

Bassetti, C; Beer, K; Beer, S; Buettner, U; Chofflon, M; Gass, A; Goebels, N; Gotschi-Fuchs, M; Kappos, L; Kesselring, J; Ludin, HP; Mattle, H; Schluep, M; Vaney, C; Baumhackl, U; Berger, T; Deisenhammer, F; Fazekas, F; Freimuller, M; Kollegger, H; Kristoferitsch, W; Lassmann, H; Markut, H; Strasser-Fuchs, S; Vass, K; Altenkirch, H; Bamborschke, S; Baum, K; Bayas, A; Benecke, R; Bruck, W; Buttmann, M; Chan, A; Daumer, M; Dommasch, D; Elias, WG; Fasshauer, E; Flachenecker, P; Gehlen, W; Gold, R; Haas, J; Haferkamp, G; Haller, P; Hartung, HP; Heesen, C; Heibel, M; Heidenreich, F; Hemmer, B; Henze, T; Hohlfeld, R; Janzen, RWC; Japp, G; Jung, S; Jugelt, E; Kallmann, B; Kieseier, BC; Kleinschnitz, C; Kohler, J; Kohler, W; Kolmel, W; Konig, N; Lehrieder, G; Leussink, V; Lowitzsch, K; Maurer, M; Manegold, U; Melms, A; Mertin, J; Neuhaus, O; Oschmann, P; Petereit, HF; Pette, M; Pohlau, D; Pohl, D; Rieckmann, P; Ruprecht, K; Sailer, M; Schipper, H; Schmidt, S; Schock, G; Schulz, M; Schwarz, S; Schwendemann, G; Seidel, D; Sommer, N; Stangel, M; Stark, E; Steinbrecher, A; Stoll, G; Toyka, KV; Tumani, H; Voltz, R; Wandinger, KP; Weber, F; Weilbach, F; Weinrich, W; Weissert, R; Wiendl, H; Wietholter, H; Wildemann, B; Zettl, UK; Ziemssen, T; Zipp, F; Zschenderlein, R; Rieckmann, P; Toyka, KV Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)
. 2006; 77(12): 1506-1518. Doi: 10.1007/s00115-006-2220-x
Web of Science PubMed FullText FullText_MUG

 

Stauber, RE; Stadlbauer, V Novel approaches for therapy of chronic hepatitis C.
J CLIN VIROL. 2006; 36(2): 87-94. Doi: 10.1016/j.jcv.2006.02.003
Web of Science PubMed FullText FullText_MUG

 

2004

Rieckmann, P; Toyka, KV; Bassetti, C; Beer, K; Beer, S; Buettner, U; Chofflon, M; Götschi-Fuchs, M; Hess, K; Kappos, L; Kesselring, J; Goebels, N; Ludin, HP; Mattle, H; Schluep, M; Vaney, C; Baumhackl, U; Berger, T; Deisenhammer, F; Fazekas, F; Freimüller, M; Kollegger, H; Kristoferitsch, W; Lassmann, H; Markut, H; Strasser-Fuchs, S; Vass, K; Altenkirch, H; Bamborschke, S; Baum, K; Benecke, R; Brück, W; Dommasch, D; Elias, WG; Gass, A; Gehlen, W; Haas, J; Haferkamp, G; Hanefeld, F; Hartung, HP; Heesen, C; Heidenreich, F; Heitmann, R; Hemmer, B; Hense, T; Hohlfeld, R; Janzen, RW; Japp, G; Jung, S; Jügelt, E; Koehler, J; Kölmel, W; König, N; Lowitzsch, K; Manegold, U; Melms, A; Mertin, J; Oschmann, P; Petereit, HF; Pette, M; Pöhlau, D; Pohl, D; Poser, S; Sailer, M; Schmidt, S; Schock, G; Schulz, M; Schwarz, S; Seidel, D; Sommer, N; Stangel, M; Stark, E; Steinbrecher, A; Tumani, H; Voltz, R; Weber, F; Weinrich, W; Weissert, R; Wiendl, H; Wiethölter, H; Wildemann, U; Zettl, UK; Zipp, F; Zschenderlein, R; Izquierdo, G; Kirjazovas, A; Packauskas, L; Miller, D; Koncan Vracko, B; Millers, A; Orologas, A; Panellus, M; Sindic, CJ; Bratic, M; Svraka, A; Vella, NR; Stelmasiak, Z; Selmaj, K; Bartosik-Psujik, H; Mitosek-Szewczyk, K; Belniak, E; Mochecka, A; Bayas, A; Chan, A; Flachenecker, P; Gold, R; Kallmann, B; Leussink, V; Mäurer, M; Ruprecht, K; Stoll, G; Weilbach, FX; Multiple Sclerosis Therapy Consensus Group Escalating immunotherapy of multiple sclerosis--new aspects and practical application.
J Neurol. 2004; 251(11):1329-1339 Doi: 10.1007/s00415-004-0537-6
Web of Science PubMed FullText FullText_MUG

 

2003

Jessner, W; Stauber, R; Hackl, F; Datz, C; Watkins-Riedel, T; Hofer, H; Gangl, A; Kessler, H; Ferenci, P Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.
J Viral Hepat. 2003; 10(1):37-42 Doi: 10.1046%2Fj.1365-2893.2003.00396.x
Web of Science PubMed FullText FullText_MUG

 

2001

Hartung, HP Current status of interferon beta-1b in multiple sclerosis therapy
Med Klin (Munich). 2001; 96 Suppl 1(5):11-16
Web of Science PubMed FullText

 

Hauschild, A; Garbe, C; Stolz, W; Ellwanger, U; Seiter, S; Dummer, R; Ugurel, S; Sebastian, G; Nashan, D; Linse, R; Achtelik, W; Mohr, P; Kaufmann, R; Fey, M; Ulrich, J; Tilgen, W Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Br J Cancer. 2001; 84(8):1036-1042 Doi: 10.1054/bjoc.2001.1731 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

1999

Ugurel, S; Seiter, S; Rappl, G; Stark, A; Tilgen, W; Reinhold, U Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-gamma.
Int J Cancer. 1999; 82(5):727-736 Doi: 10.1002/(SICI)1097-0215(19990827)82:5<727::AID-IJC17>3.0.CO;2-E
Web of Science PubMed FullText FullText_MUG

 

Zimmermann, C; Walther, EU; Goebels, N; Lienert, C; Kappos, L; Hartung, HP; Hohlfeld, R Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis
Nervenarzt. 1999; 70(8):759-763 Doi: 10.1007/s001150050508
Web of Science PubMed FullText FullText_MUG

 

1994

Marth, C; Weiss, G; Koza, A; Reibnegger, G; Daxenbichler, G; Zeimet, AG; Fuchs, D; Wachter, H; Dapunt, O Increased production of immune activation marker neopterin by colony-stimulating factors in gynecological cancer patients.
Int J Cancer. 1994; 58(1):20-23 Doi: 10.1002/ijc.2910580105
Web of Science PubMed FullText FullText_MUG Google Scholar

 

1993

Pummer, K; Lehnert, M; Seewann, HL Chemohormonal and immunohormonal approaches in advanced prostatic carcinoma.
Eur Urol. 1993; 24 Suppl 2(3A):81-86 Doi: 10.1159/000474397
Web of Science PubMed FullText FullText_MUG

 

1990

Werner-Felmayer, G; Werner, ER; Fuchs, D; Hausen, A; Reibnegger, G; Wachter, H Neopterin formation and tryptophan degradation by a human myelomonocytic cell line (THP-1) upon cytokine treatment.
Cancer Res. 1990; 50(10):2863-2867 [OPEN ACCESS]
Web of Science PubMed FullText Google Scholar

 

1988

Bitterlich, G; Szabó, G; Werner, ER; Larcher, C; Fuchs, D; Hausen, A; Reibnegger, G; Schulz, TF; Troppmair, J; Wachter, H Selective induction of mononuclear phagocytes to produce neopterin by interferons.
Immunobiology. 1988; 176(3):228-235 Doi: 10.1016/S0171-2985(88)80055-X
Web of Science PubMed FullText FullText_MUG Google Scholar

 

1984

Huber, C; Batchelor, JR; Fuchs, D; Hausen, A; Lang, A; Niederwieser, D; Reibnegger, G; Swetly, P; Troppmair, J; Wachter, H Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma.
J Exp Med. 1984; 160(1):310-316 Doi: 10.1084/jem.160.1.310 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum